Craig Ivan Turner

USPTO Granted Patents = 9 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

Stanmore, AU (2013)
New South Wales, AU (2016 - 2018)
Frenchs Forest, AU (2020 - 2021)

Company Filing History:

Boehringer Ingelheim International Gmbh

Years Active: 2013-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428370 - Haloallylamine dual amine oxidase inhibitors (2025-09-30),

2. 12178791 - Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof (2024-12-31),

3. 11098045 - Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof (2021-08-24),

4. 10717734 - Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof (2020-07-21),

5. 10717733 - Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof (2020-07-21),

6. 10160723 - Substituted 3-haloallylamine inhibitors of SSAO and uses thereof (2018-12-25),

7. 9815782 - Substituted 3-haloallylamine inhibitors of SSAO and uses thereof (2017-11-14),

8. 9302986 - Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof (2016-04-05),

9. 8426587 - Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor (2013-04-23),

Title: Craig Ivan Turner: Innovator in Pharmaceutical Compounds

Introduction

Craig Ivan Turner is a notable inventor based in Frenchs Forest, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various neuromuscular and neuroinflammatory diseases. With a total of nine patents to his name, Turner's work has the potential to impact both human health and veterinary medicine.

Latest Patents

One of Turner's latest patents is for Haloallylamine dual amine oxidase inhibitors. This invention relates to novel compounds capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treating a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. Additionally, the patent includes pharmaceutical compositions containing these compounds and various uses thereof.

Another significant patent is for Haloallylamine sulfone derivative inhibitors of lysyl oxidases. This invention focuses on novel compounds that inhibit certain amine oxidase enzymes. These compounds are beneficial for treating various conditions, including fibrosis, cancer, and angiogenesis in both human subjects and animals. Similar to his previous patent, this invention also encompasses pharmaceutical compositions and their uses.

Career Highlights

Throughout his career, Craig Ivan Turner has worked with prominent companies in the pharmaceutical industry, including Pharmaxis Ltd. and Boehringer Ingelheim International GmbH. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Turner has collaborated with notable professionals in his field, including Mandar Deodhar and Jonathan Stuart Foot. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.

Conclusion

Craig Ivan Turner is a distinguished inventor whose work in pharmaceutical compounds has the potential to revolutionize treatments for various diseases. His innovative patents and collaborations reflect his commitment to advancing medical science and improving health outcomes for both humans and animals.

This text is generated by artificial intelligence and may not be accurate.